Cite

HARVARD Citation

    Dadu, R. et al. (2014). Efficacy and Tolerability of Different Starting Doses of Sorafenib in Patients With Differentiated Thyroid Cancer. Oncologist. pp. 477-482. [Online]. 
  
Back to record